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1. Introduction  
The pivotal role of kinases in signal transduction and cellular regulation has lent them 
considerable appeal as therapeutic targets across a broad spectrum of cancers. The 
epidermal growth factor receptor (EGFR) was the first receptor tyrosine kinase to be 
discovered and remains the most investigated. Most of the mechanistic principles of 
receptor tyrosine kinases were first established with the EGFR family as a model. EGFR is a 
single pass transmembrane receptor with two extracellular, cysteine-rich regions involved in 
ligand binding, and intervening region important for receptor dimerization, an intracellular 
tyrosine kinase domain, and a number of intracellular sites for autophosphorylation, 
phosphorylation by other kinases, and docking of signaling components. Three additional 
EGFR family members have been identified, human epidermal growth factor receptor (erbB 
or HER) 2, 3 and 4. In many cell types, including those of epithelial and mesenchymal 
lineages, receptors of the HER family transduce signals from the cell surface to the 
intracellular domain, regulating normal cell growth, lineage determination, repair and 
functional differentiation. A range of growth factors serves as ligands for these receptors, 
although none have been identified for the HER2 receptor. Ligands for HER1/EGFR include 
epidermal growth factor (EGF) and transforming growth factor-α (TGF-α), and heregulins 
serve as ligands for both HER3 and HER4. Binding of a ligand to a HER family member 
leads to receptor homodimerization, or heterodimerization with another HER receptor, 
bringing about receptor phosphorylation. Ligand binding to HER1, HER3 or HER4 induces 
rapid receptor dimerization, with a marked preference for HER2 as a partner(Graus-Porta et 
al., 1997). Moreover, HER2-containing heterodimers generate intracellular signals that are 
significantly more potent than signals emanating from other HER combinations. Of the 
receptor dimers, HER3 homodimers cannot initiate signal transduction.The differing 
signaling characteristics of the HER family members are thought to be due to their different 
ligand-binding affinities and the type of phosphorylated homo- or heterodimer formed, and 
the resulting intracellular signaling events. Two of the key pathways involved in this 
cascade are the ras-raf-mitogen-activated protein kinase (MAPK) pathway, which affects 
DNA synthesis and cell proliferation, and the phosphatidylinositol 3-kinase (PI3-K)/Akt 
pathway, which plays a role in cell metabolism and survival (Yarden and Sliwkowski, 2001; 
Bange et al., 2001). 
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Functional dysregulation of the EGFR family is frequently observed in human cancers, 
suggesting that its signal modulates processes that play a pivotal role in tumorigenesis and 
disease progression. Activating mutations, gene amplification and overexpression of HER 
family kinases have been implicated as integral contributors to a variety of epithelial 
cancers, including breast, colon, pancreas, lung, and squamous cancers and also 
glioblastomas(Yarden, 2001; Foley et al., 2010; Yarom and Jonker, 2011; Wheeler et al., 2010; 
Dobashi et al., 2011; Machiels and Schmitz, 2011; Hwang, 2008). This is highlighted by 
HER1/EGFR overexpression or activation by autocrine or paracrine growth factor loops in 
at least 50% of epithelial malignancies, HER2 amplification and overexpression in 
approximately 20–25% of breast cancers and variable HER3 and HER4 expression in breast 
and other cancers. Overexpression and/or activation of HER1/EGFR, HER2/neu and HER3 
have been correlated with poor prognosis. In contrast, it is unclear whether HER4 induces 
cell division or differentiation, and there is controversy regarding its role in breast cancer, 
with conflicting reports associating overexpression with shorter or prolonged survival 
(Normanno et al., 2006). Therefore, attenuation of HER family signaling is a developing 
strategy for the management of human malignancies and is the subject of a number of 
ongoing clinical trials. 
Signaling from the plasma membrane by receptor tyrosine kinases (RTKs) to initiate 
downstream events that bring about their biological effects is well established.  In the past 
decade, it has become increasingly apparent that several RTKs also move to several 
intracellular compartments, with nuclear localization in many cases being necessary for full 
function of the receptors. Access to the inside of the cell by the RTKs has in fact been shown 
to contribute to genesis and progression of a variety of human tumors (Carpenter, 2003). 
Accruing evidence points to a scenario where nuclear localization of EGFR in different 
tumor types has impact on not only the tumor grade but also on the resistance of tumors to 
therapies (Lo et al., 2006b; Wang and Hung, 2009). Here we critically evaluate the existing 
literature regarding intracellular localization of EGFR and its importance to cancer, and 
discuss future directions for the field. Further, the opportunity for targeting nuclear 
translocation of EGFR to develop therapeutics for intervention during critical stages of 
development and progression of neoplasms should be evaluated. There are numerous 
excellent recent reviews of HER family biology, signaling and therapeutic targeting (Yarden, 
2001; Yarden and Sliwkowski, 2001; Foley et al., 2010; Yarom and Jonker, 2011; Wheeler et 
al., 2010; Hwang, 2008). This chapter will provide an overview of aberrant EGFR signaling 
in the biology of gliomas highlighting several key developments in the rapidly evolving 
area of HER family biology with specific reference to new localization of EGFR and the 
integral role of these receptors in malignant transformation and as targets of cancer therapy 
specifically in glioblastomas. 
2. EGFR in glioma 
Although a large number of other genetic alterations also occur in GBM, EGFR represents 
the most frequently amplified gene (2008; Hatanpaa et al., 2010). In fact, in primary GBM, it 
has been noted for about two decades and confirmed recently with two large-scale cancer 
genomics studies that EGFR amplification and mutation is a recurrent occurrence, being 
detected in about 40% of the samples (2008; Parsons et al., 2008). However, this is a rare 
event in low-grade gliomas (Ohgaki and Kleihues, 2007), suggesting a causal role for 
aberrant EGFR signaling in the pathogenesis of primary GBM. The resulting dysregulation 
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of the signal transduction process affects gene transcription and protein translation, 
stimulating tumor cell proliferation, tumorigenesis, migration, adhesion and angiogenesis, 
and inhibiting apoptosis (Huang et al., 2009). Recent research has shown an unfavorable 
prognostic relationship between EGFR amplification and overall survival in patients with 
GBM (Aldape et al., 2004; Heimberger et al., 2005; Pelloski et al., 2007). EGFR expression is 
also associated with enhanced resistance to radiation in malignant GBM cells in vitro and is 
correlated with poor radiographic response to radiation therapy in some patients with GBM 
(Nakamura, 2007; Hatanpaa et al., 2010). EGFR dysregulation in GBM result from a number 
of different mechanisms. Primarily, gene amplification causes EGFR overexpression, which 
correlates with disease progression, poor prognosis and reduced sensitivity to 
chemotherapy. In addition, overproduction of EGFR ligands, such as TGF-α and EGF can 
cause autocrine receptor activation, enhancing transformation and leading to independent 
tumor cell growth. Further, activating mutations in EGFR generates EGFR mutants that 
demonstrate constitutive activity resulting in activation of the downstream intracellular 
cascade without ligand binding and insensitivity to regulation by normal cellular controls 
(Hwang, 2008). 
While there are various mutant forms of EGFR in GBM, the most prevalent and well studied 
EGFR mutation is EGFRvIII (Hwang, 2008). EGFRvIII is detected in about half of all  
tumors with EGFR amplification (Aldape et al., 2004; Heimberger et al., 2005). 
Immunohistochemical and quantitative PCR studies of human GBM biopsies suggest that in 
most tumors the overexpression or amplification of EGFRvIII occurs concurrently with that 
of EGFR. Only in about 10% of glioblastomas does overexpression or amplification of 
EGFRvIII exceed that of the wild-type receptor (Sugawa et al., 1990; Furnari et al., 2007). In 
addition to GBM, EGFRvIII has been detected in several human cancers including NSCLC 
and breast carcinomas (Moscatello et al., 1995; Ge et al., 2002; Ji et al., 2006; Sasaki et al., 
2007). Structurally, EGFRvIII exhibits a large inframe deletion of the extracellular ligand 
binding domain which results from the elimination of a 801 base pair (nucleotide positions 
275–1075) DNA fragment containing exons 2–7 of the gene (Sugawa et al., 1990; Ekstrand et 
al., 1991; Wong et al., 1992; Frederick et al., 2000). This partial deletion of the ligand-binding 
domain renders EGFRvIII ligand insensitive and also constitutively activated. The ability of 
this variant to ‘switch on’ cell signaling without ligand stimulation, albeit at low levels, 
results in increased oncogenic signaling and aggressive behavior in tumors that express it 
(Huang et al., 1997; Nishikawa et al., 1994; Chu et al., 1997). Further, it has a low rate of 
receptor endocytosis, so is not readily attenuated and/or down-regulated (Chu et al., 1997; 
Huang et al., 1997). EGFRvIII correlates with advanced disease and resistance to therapy 
(Hwang, 2008). Several studies have found that it enhances tumorigenicity in human glioma 
xenografts in mice. The introduction of EGFRvIII into glioma cells enhances tumorigenicity, 
proliferation, migration, and inhibits apoptosis (Huang et al., 1997; Nagane et al., 1996; 
Nagane et al., 2001). In a transgenic mouse model, EGFRvIII was found to contribute to 
glioma progression in the presence of other predisposing genetic changes, such as mutated 
RAS, but failed to initiate tumors on its own (Holland et al., 1998; Bachoo et al., 2002; Ding et 
al., 2003). Furthermore, there is growing evidence from in vitro studies in human 
glioblastoma cells, human tumor xenografts in animal models, and in patients with GBM, to 
suggest that EGFRvIII promotes tumor growth and progression in part via constitutive 
activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway (Choe et al., 2003; 
Aldape et al., 2004; Mizoguchi et al., 2006; Pedersen et al., 2005; Huang et al., 2007). The role 
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of the mitogen-activated protein kinase (MAPK)/ERK 1/2 signal transduction pathway 
downstream of EGFRvIII is still unclear. Constitutive activity as well as impaired 
attenuation has been implicated as mechanisms for the enhancement of human glioblastoma 
cell tumorigenicity by EGFRvIII as compared to wild-type EGFR. Further, it has been 
recently demonstrated that EGFRvIII overexpression results in secretion of IL-6 and other 
cytokines to potentiate tumorigenesis in a paracrine manner (Inda et al., 2010). These data 
may explain the observation that patients with EGFRvIII-expressing tumors have a shorter 
interval to clinical relapse and poorer survival than patients with EGFRvIII-negative tumors. 
For GBM patients who survive 1 year or longer after diagnosis, the expression of EGFRvIII 
is also an independent negative prognostic indicator of survival (Aldape et al., 2004; 
Heimberger et al., 2005; Pelloski et al., 2007), which makes EGFRvIII an ideal target for 
antitumor therapy. 
Signaling pathways are complex, multidimensional events that frequently converge, 
diverge, and cross talk with one another. The traditional cellular functions of EGFR and 
EGFRvIII has been reviewed elsewhere; this review focuses specifically on the role played 
by EGFR and EGFRvIII in the nuclear compartment as well as its nuclear downstream 
effectors in a number of human malignancies, and the possible novel therapeutic 
opportunities provided for development of anti-tumor agents. 
3. EGFR/EGFRvIII in mitochondria 
In the past decade, it has become increasingly apparent that several RTKs, including EGFR 
act also from intracellular organelles wherein they elicit biological effects that are uniquely 
distinct from their cell-surface functions. In addition to translocation to the nucleus (which is 
described in detail in the next sections), EGFR also localizes to the mitochondria, where it 
interacts with COXII and regulates cell survival in an EGFR Tyr845-dependent manner 
(Boerner et al., 2004). Src can activate EGFR by phosphorylating it on the Tyr845 and 
interestingly, the kinetics of mitochrondrial localization of both EGFR and Src (which also 
undergoes mitochondrial import) seem to be similar suggesting that they might translocate  
in the same complex (Demory et al., 2009). While the complete mechanism by which EGFR 
translocates to the mitochondria has not yet been defined, a recent investigation revealed 
that both EGFR and Src kinase activity was essential for mitochondrial translocation. 
Further, the same group identified that a mitochondrial localization signal in the 
juxtamembrane region of EGFR (residues 645 to 666) as well as the endocytic pathway are 
important for the movement of EGFR to the mitochondrion (Demory et al., 2009).  Since the 
fusion of endosomes with mitochondria has not been demonstrated, the actual process by 
which endosomal EGFR moves to the mitochondria is still open to investigation. However, 
it was also shown that EGFR interacted with Tom40 (Demory et al., 2009), the pore 
component of the TOM complex and an outer mitochondrial membrane transport protein 
that is necessary for transport of newly synthesized mitochondrial proteins encoded by 
nuclear DNA. This suggests that EGFR could utilize the TOM complex to enter the 
mitochondria.  Further, a report also demonstrated that EGFR translocates to the 
mitochondrion during autophagy where it again promoted cell survival (Yue et al., 2008), 
implying that mitochondrial localization of EGFR could potentially be an important survival 
strategy for cells. The same study showed that EGFR mitochondrial translocation can be 
increased by the mTOR inhibitor, rapamycin, and decreased by the topoisomerase inhibitor, 
etoposide, and by 3'-methyladenine, an inhibitor of autophagy. The reported link between 
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autophagy and mitochondrial EGFR is particularly interesting due to the recent observation 
that apoptotic stress induces EGFR mitochondrial transport. Given the pivotal role that 
mitochondria plays in intrinsic apoptosis, a study by Cao et al (Cao et al., 2011) show that 
not only EGFR but EGFRvIII can also translocate to the mitochondria when induced by 
apoptosis-inducing agents and EGFR kinase inhibitors(Iressa) and that tumor cells with 
accumulated mitochondrial EGFRvIII are resistant to apoptosis induced by these 
agents. These results implicate mitochondrial EGFR/EGFRvIII in the modulation of 
mitochondria-mediated apoptosis. Taken together these studies suggest that tumor cells re-
program their intracellular trafficking of EGFR/EGFRvIII  by increasing its mitochondrial 
accumulation, as a mechanism for escape from therapy- and stress-induced apoptosis and 
growth suppression. 
4. EGFR in the nuclear compartment 
In addition to ligand recognition, binding, and initiation of intracellular signaling cascades, 
receptor tyrosine kinases such as the EGFR family have newly emerging roles in the 
regulation of nuclear functions through their direct translocation to the cell nucleus. Broadly 
speaking two kinds of nuclear translocation have been identified: EGFR, HER2 and HER3 
have been found as full-length proteins in the nuclear compartment and this will be our 
focus here; in contrast HER4 nuclear translocation and transactivation functions occur 
through a separate mechanism involving cleavage by matrix metalloprotease of the 
extracellular domain upon receptor activation, and cleavage of the intracellular domain by 
gamma secretase, releasing a protein fragment that translocates to the nucleus (Carpenter, 
2003). This carboxyl-terminal HER4 fragment then associates with the WW-domain-
containing transcriptional regulatory protein YAP (Yes-associated protein) and acts as a co-
transcriptional activator (Ni et al., 2001). The physiological and clinical importance of 
nuclear EGFR has been underscored by the observation that presence of EGFR in the nuclear 
compartment in tumor biopsies correlates strongly with poor prognosis and resistance to 
standard treatment modalities (Wang and Hung, 2009).  
4.1 Nuclear localization and function 
Almost two decades of research have documented the presence of EGFR and its ligand EGF 
in the nucleus. Early studies focused on EGF localization and demonstrated that nuclear 
presence of intact EGF was dependent on the expression of EGFR (Rakowicz-Szulczynska et 
al., 1986; Rakowicz-Szulczynska et al., 1989). The use of labeled EGF enabled definitive 
documentation that nuclear EGF was derived from extracellularly added ligand (Rakowicz-
Szulczynska et al., 1989). The same studies demonstrated that the nuclear membranes and 
isolated chromatin contained EGFR which was indistinguishable from plasma membrane 
localized EGFR both biochemically and immunologically (Rakowicz-Szulczynska et al., 
1989; Oksvold et al., 2002; Cao et al., 1995; Marti et al., 1991; Marti and Wells, 2000). Further, 
EGF could stimulate phosphorylation of nuclear EGFR and other nuclear proteins in 
isolated nuclei and nuclear membranes, and could be specifically inhibited by monoclonal 
antibodies directed against the extracellular domain of cell surface EGFR (Holt et al., 1994). 
In normal tissues, nuclear expression of EGFR has been shown to be associated with the 
acquisition of proliferative capabilities of the cell. In hepatocytes which start proliferating 
after hepatectomy, nuclear EGFR was detected. In contrast, quiescent hepatocytes did not 
show nuclear EGFR (Marti et al., 1991). EGFR was also identified in the nucleus of mouse 
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lung epithelial cells where it was shown to respond to neuregulin stimulation(Zscheppang 
et al., 2006). Additionally, functional nuclear EGFR was demonstrated in human placenta 
where its role as a transcription factor was put forth (Cao et al., 1995). Further, nuclear 
localization of EGFR was demonstrated in primary human umbilical venous endothelial 
cells (HUVEC) and arterial endothelial cells (HUAEC) derived from early fetal gestation 
(Bueter et al., 2006). 
Three basic functions of nuclear EGFR have been defined thus far (Figure 1). They are 
1. gene regulation/transactivation, 
2. tyrosine phosphorylation of target proteins and  
3. protein-protein interactions leading to DNA repair  
 
 
Fig. 1. Schematic representation of nuclear functions of EGFR. The cartoon shows both 
traditional cytoplasmic signaling eliciting nuclear effects as well as the more recently 
identified nuclear translocation and direct nuclear effects. Adapted from (Lo et al., 2006c) 
4.1.1 Regulation of transcription 
Although nuclear localization and potential transcriptional activity of EGFR had been noted 
in previous publications, Lin et al. demonstrated for the first time the presence of a strong 
transactivation domain in the C-terminal Pro-rich domain of EGFR, which mediated nuclear 
transactivation functions in a sequence-specific fashion (Lin et al., 2001). Although an EGFR 
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mutant which lacked the transmembrane domain could also translocate to the nucleus, this 
movement required both wild type EGFR and active ligand signaling (Marti and Wells, 
2000). Upon ligand stimulation, EGFR translocated to the nucleus and associated with an 
A/T-rich sequence (ATRS) in the cyclin D1 promoter, resulting in transcriptional activation 
of cyclin D1. This study thus defined a direct link between nuclear EGFR function and cell 
proliferation specifically in tumors (Lin et al., 2001). Interestingly, it had been shown about a 
decade earlier that for induction of a mitogenic response, amphiregulin, one of the ligands 
of EGFR, had to undergo nuclear translocation where it bound to AT-rich DNA sequences 
(Kimura, 1993). Since EGFR lacks a putative DNA-binding domain, the wide-held idea in 
the field is that EGFR first associates with DNA-binding transcription factors and then 
enhances target gene transcription via their intrinsic transactivational activity. Another 
mechanism underlying nuclear EGFR-mediated gene regulation could be attributed to its 
interaction with mucin 1 (MUC1) wherein there is increased accumulation of chromatin-
bound EGFR on cyclin D1 promoter and significant co-localization with phosphorylated 
RNA polymerase II, a marker of active transcription (Bitler et al., 2010). A recent study 
showed that EGFR was also able to associate with ATRS sites on DNA by association with 
RNA helicase A (RHA), a DNA and RNA binding protein (Huo et al., 2010). This association 
was found to be absolutely necessary for EGFR recruitment to the ATRS site of cyclin D1 
promoter and partially necessary for recruitment onto another ATRS-containing promoter 
of inducible nitric oxide synthase (iNOS) gene (Huo et al., 2010). The partial role of RHA in 
EGFR regulation of iNOS could be because nuclear EGFR has been shown to get recruited to 
iNOS promoter via physical protein-protein interaction with the well characterized 
transcription factor, signal transducer and activator of transcription 3 (STAT3) (Lo et al., 
2005a). Physical interaction and functional cooperation of EGFR with STAT3 at the 
cytoplasmic level is very well characterized. According to this classical model, active EGFR 
at the plasma membrane binds to the SH2 domain of STAT3, via the two docking 
autophosphorylated tyrosines (Tyr1068 and Tyr1086)(Shao et al., 2003). This interaction 
leads to the phosphorylation of STAT3 at Tyr705 and its activation. The dimeric STAT 
complex translocates to the nucleus, where it binds to specific DNA promoter sequences, 
recruits other transcriptional regulators, and activates the transcription of multiple genes 
important for cell survival (Shao et al., 2003). However, data now show that EGFR can 
interact with STAT3 in the nucleus where they form a complex that functions as a 
transcriptional activator for the iNOS gene (Lo et al., 2005a) and the Cox-2 gene (Lo et al., 
2010), allowing for the possibility that STAT activation is not an exclusively plasma 
membrane/cytosolic event. Further, iNOS gene expression was also induced by nuclear 
EGFR in reactive astrocytes of human glaucomatous optic nerve head, implying an 
important role for nuclear EGFR in other diseases besides cancers (Liu and Neufeld, 2003). 
Furthermore, cooperation of nuclear EGFR with the transcription factor E2F1 activates 
expression of B-Myb, a positive regulator of G1/S cell-cycle progression (Hanada et al., 
2006). Thus, B-Myb joins cyclin D1 as another transcriptional target of nuclear EGFR that 
promotes cell proliferation. 
Another member of the STAT family that associates with EGFR in both the cytoplasmic and 
nuclear compartment is STAT5. There are two STAT5 proteins, STAT5A and STAT5B, which 
are encoded by two distinct but closely related genes. STAT5A has a higher DNA-binding 
affinity than STAT5B, and it is mostly involved in prolactin-directed mammary gland 
maturation (Grimley et al., 1999), whereas STAT5B is believed to be involved in the response 
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to the growth hormone. Similar to STAT3, unphosphorylated STAT5 is present in the 
nucleus and cytoplasm, and it constitutively shuttles in and out of the nucleus (Zheng et al., 
2002). The N terminus is required for the constitutive nuclear import of STAT5, although the 
precise nature of its nuclear import domain remains to be determined. Following tyrosine 
phosphorylation, STAT5 accumulates in the nucleus where it induces its biological effects by 
transcriptional control of target genes (Debierre-Grockiego, 2004). As observed with STAT3, 
EGFR interacts with STAT5 on the ATRS motif to transactivate the Aurora-A promoter . 
Increased expression of the Aurora-A gene induced centrosome amplification and 
microtubule disorder (Hung et al., 2008). Further, studies from our laboratory have shown 
that EGFR can also associate with STAT5b to regulate Bcl-XL expression (Latha et. al., 
manuscript in preparation). Our study also showed a significant correlation between 
phosphoSTAT5b and EGFR expression in human GBMs. Furthermore, semi-quantitative 
scoring showed that patients whose tumors had detectable phosphoSTAT5 had a worse 
clinical outcome when compared to patients whose tumors had no detectable 
phosphoSTAT5 (Latha et. al., manuscript in preparation).  
4.1.2 Nuclear substrates of EGFR  
That the nucleus is an important site of direct action on the part of EGFR is supported by 
studies showing that exogenously added EGF can stimulate autophosphorylation of the 
EGFR, along with stimulation of phosphorylation of other non-EGF-binding proteins in 
isolated nuclei and nuclear membranes (Holt et al., 1994). Further, use of monoclonal 
antibody directed against the extracellular domain of EGFR inhibited the phosphorylation 
induced by EGF in isolated nuclei (Holt et al., 1994; Cao et al., 1995). Thus, apart from 
functioning as a transcriptional coregulator to modulate gene expression, the regulated 
kinase activity of EGFR in the nucleus can control the activation state of nuclear factors and 
thereby gene expression as well as other functions of such nuclear factors. The only direct 
nuclear substrate identified thus far is proliferating cell nuclear antigen (PCNA) (Wang et 
al., 2006).   Wang et al. showed that nuclear EGFR phoshorylates chromatin-bound PCNA 
on Tyr211, and this phosphorylation is required for maintaining PCNA function on 
chromatin.  Inhibition of the phosphorylation led to degradation of the chromatin-bound, 
but not the unbound, form of PCNA in a proteasome-dependent manner and consequently 
suppressed its function in DNA synthesis and DNA damage repair (Wang et al., 2006). This 
important finding raised the possibility that additional nuclear proteins may be 
phosphorylated by nuclear EGFR and their functions, stability, and/or subcellular 
localization altered as a consequence of tyrosine phosphorylation. Future efforts are needed 
to explore this possibility. 
4.1.3 Regulation of DNA repair by nuclear EGFR 
In addition to ligand-induced accumulation of EGFR in the nucleus, EGFR has been 
demonstrated to escape receptor degradation after internalization and translocate to the 
nucleus in response to stress signals such as ionizing radiation, heat shock, H2O2, and 
cisplatin (Rodemann et al., 2007).  Specifically, ionizing radiation causes nuclear transport of 
EGFR via caveolin and protein kinase C dependent mechanisms (Khan et al., 2006). Further, 
radiation has also been shown to drive EGFR translocation from the perinuclear region to 
the nucleoplasm via a process involving generation of free radicals (Dittmann et al., 2005a). 
Also, ultraviolet irradiation has been shown to induce EGFR nuclear translocation in human 
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keratinocytes (Xu et al., 2009). In addition, Bandyopadhyay et al. reported that nuclear 
EGFR can influence DNA repair directly via physical interaction with DNA-dependent 
kinase (DNA-PK). They showed that cetuximab, an EGFR neutralizing antibody could 
decrease nuclear DNA-PK protein and kinase activity (Bandyopadhyay et al., 1998). 
Cetuximab treatment was also shown to block nuclear shuttling of EGFR and increased 
sensitivity to radiation-induced cell death in these cells (Dittmann et al., 2005b). It was also 
shown that the presence of EGFR in the nucleus resulted in activation of DNA-PK as shown 
by its phosphorylation on Thr2609. In the same study, it was again demonstrated that 
nuclear EGFR binds to the catalytic subunit DNA-PKs, and the regulatory subunit Ku70 of 
DNA-PK (Dittmann et al., 2005b). Nuclear EGFR has been shown to associate with p53 and 
MDC1 protein, an essential protein for the recruitment of DNA repair foci, following 
irradiation and treatment with the radioprotector Bowman-Birk proteinase inhibitor 
(Gueven et al., 1998; Dittmann et al., 2008a). Another radioprotector O-phospho-l-tyrosine 
(P-Tyr) has been shown to activate PKCepsilon, which triggers nuclear EGFR accumulation 
and concurrent phosphorylation of DNA-PK at amino acid residue Thr2609, and leads to 
repair of DNA double-strand breaks (Dittmann et al., 2007). Together these observations 
suggest an important role of nuclear EGFR for regulation of DNA repair following 
treatment with genotoxic substances. 
4.2 Mechanism of nuclear transport 
The intact EGFR protein containing both intracellular and extracellular domains moves to 
the nucleus in a ligand-bound form and the mechanism of this translocation is still 
incompletely understood.  A seminal study very clearly demonstrated that intact EGFR 
bound by monoclonal antibodies directed against extracellular residues can accumulate 
specifically in the nucleus only in EGFR-expressing cells (Holt et al., 1994). This provided 
the first clue that endocytic events associated with the plasma membrane receptor could 
lead to intracellular trafficking and the delivery of EGFR to the nucleus. Further studies 
have convincingly demonstrated that a novel pathway exists by which internalized EGFR in 
the early endosomes is transferred into the nucleus instead of lysosomes or being recycled to 
the cell surface.  Inhibition of receptor endocytosis using a dominant-negative dynamin 
mutant, which abrogates the formation of clathrin-coated pits from the cell surface, blocks 
the nuclear transport of EGFR (Lo et al., 2006a). Further, EGFR has been shown to colocalize 
with EEA1, an early endosomal marker in the nuclear compartment (Giri et al., 2005; Lo et 
al., 2006a). Thus, it seems clear that EGFR utilizes the endocytic pathway for its translocation 
into the nucleus, though additional routes cannot be excluded. 
Nuclear localization requires recognition by the cellular nuclear import machinery and, in 
particular, by members of the nuclear localization sequence (NLS)-recognizing IMP 
superfamily. The best-understood NLS dependent nuclear import pathway is that mediated 
by the IMPα/β heterodimer. After irradiation, it was demonstrated that EGFR is found in 
complex with Importin α and RAN-GTP. It was also shown that EGFR-dependent activation 
of the PI3K/AKT signaling pathway was important for this association (Dittmann et al., 
2005a). A prerequisite for Importin binding is the presence of an NLS within the cargo 
protein. EGFR has been shown to contain a tripartite NLS in its juxtamembrane region that 
mediates the nuclear translocation. EGFR has also been demonstrated to interact with 
importins α1/β1 for which the NLS appears to be indispensable (Lo et al., 2006a; Lin et al., 
2001; Hsu and Hung, 2007). Interestingly, another group studying nuclear transport of 
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EGFR following irradiation observed phosphorylation of EGFR at residue T654, which is 
located within the EGFR NLS. Furthermore, the same group identified PKCepsilon as the 
kinase responsible for this modification (Wanner et al., 2008). Nuclear EGFR accumulation 
results from a balance of import and export processes. Recent evidence also showed that the 
CRM1 is involved in nuclear–cytoplasmic shuttling of EGFR (Lo et al., 2006a). Existence of 
nuclear export sequences within EGFR sequence, however, has not yet been demonstrated.  
While the above delineated mechanisms shed light on the mechanics of nuclear 
translocation of EGFR, it still is unclear how a transmembrane receptor is processed into a 
nuclear non-membrane-bound receptor. A protein translocon mediates the trafficking of 
protein complexes into and out of lipid bilayers.  It was first suggested by Liao & Carpenter 
that the Sec61 translocon could mediate nuclear transport of EGFR (Liao and Carpenter, 
2007). The Sec61 translocon is located in the endoplasmic reticulum and mediates the 
trafficking of secretory and transmembrane proteins into the ER during protein sythesis. 
This translocon is bidirectional and functions also, as part of the ERAD pathway, to 
retrotranslocate malfolded transmembrane proteins from the ER to the cytoplasm. Studies 
showed that radiation and EGF induced trafficking of EGFR to the ER membrane 
presumably via membrane fusion of the late edosomes to the golgi apparatus where it 
interacted with the Sec61 translocon. The data showed that knock-down of a Sec61 subunit 
abrogates both EGFR nuclear localization and EGF induction of cyclin D1 (Liao and 
Carpenter, 2007).  While it has been proposed that Sec61 associated EGFR is 
retrotranslocated to the cytoplasm and subsequently imported into the nucleus via 
Importinβ and the nuclear pore complex (NPC), a recent study showed that Sec61β present 
in the inner nuclear membrane (INM) mediates retrotranslocation of EGFR from the INM 
into the nucleus (Wang et al., 2010b). Since the ER membrane system is contiguous with the 
outer nuclear membrane (ONM) and it is known that the ONM connects to the INM at the 
NPCs, it presents a model where EGFR is traficked first to ER via the endocytic machinery, 
then to the INM and then released into the nucleus by retrograde translocation at the NPC 
(Figure 2). 
4.3 Nuclear EGFR in the clinical setting 
Over the last 20 years, multiple reports have demonstrated beyond doubt that EGFR can 
translocate into the nuclear compartment where it has specific functions as outlined above. 
Concurrent studies have also identified that nuclear localization of EGFR is a common 
component of numerous cancer types. In addition to rapidly proliferating cells, nuclear 
EGFR has been detected in glioma as well as cancers of the breast, epidermoid, bladder, 
ovary, and oral cavity (Wang and Hung, 2009). 
Increased nuclear EGFR expression is a prognostic feature in multiple tumor types 
correlating with parameters of known prognostic significance, such as tumor grade, stage 
and metastasis and is also associated with resistance to standard therapy such as radiation 
and cisplatin (Wang and Hung, 2009; Hwang, 2008). Analysis of nuclear localization of 
EGFR in human breast carcinoma biopsy samples demonstrated that nuclear EGFR levels 
inversely correlated with survival and correlation existed between nuclear localization of 
EGFR and markers of proliferation such as Cyclin D1 (that was shown to be a transcriptional 
target of EGFR in the same study) and Ki-67 (Lin et al., 2001). A follow up study also 
showed positive correlation between nuclear EGFR, Cyclin D1 and RHA expression in 
breast tumors (Huo et al., 2010). Early investigations revealed that cases with high nuclear 
EGFR demonstrated a trend towards poor survival in oral carcinomas (Lo et al., 2005b). This 
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was later corroborated by studies that showed that nuclear EGFR was associated with 
increased local recurrence rate and inversely correlated with disease free survival (Psyrri et 
al., 2005). A study in esophageal squamous cell carcinoma using antibodies specific for 
phosphorylated EGFR showed that pEGFR not only localized to the nucleus but also 
correlated with higher TNM stage, nodal metastasis, and poor patient outcome (Hoshino et 
al., 2007). A follow up analysis by the same group showed that there was a strong 
correlation between nuclear EGFR and PCNA as well as nuclear ERK2 and non-nuclear 
EGFR (Psyrri et al., 2008). The above study was in line with earlier findings that PCNA is a 
substrate for EGFR in the nucleus and PCNA Tyr211 phosphorylation was associated with 
pronounced increase in cell proliferation and worse survival of breast cancer patients (Wang 
et al., 2006). A recent study also demonstrated that an inverse correlation exists between 
increased nuclear localization of EGFR and overall survival in ovarian tumor samples (Xia et 
al., 2009).  
 
 
 
Fig. 2. A cartoon depicting the transport of EGFR from the plasma membrane to the nucleus. 
The current model shows the role of endocytosis for movement of EGFR to the early 
endosome, Golgi and thereafter, to the ER. From the ER, it is assumed that EGFR moves to 
the ONM and then via the NPC and Importinβ to the INM. On INM, it associates with 
Sec61β and through retrograde transport is released into the nucleoplasm. Nuclear export 
occurs via CRM1. The dotted lines represent potential pathways while solid lines depict 
pathways that have been experimentally proved. After (Wang et al., 2010a) 
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These clinical correlations of nuclear EGFR expression underscore the importance of 
examining the role of nuclear EGFR in other cancers especially those of epithelial origin as 
well as other human diseases. In this context, interestingly in addition to cancers, 
localization of EGFR in the nuclear compartment has also been implicated in glaucoma and 
neuropathy of the optic nerve (Liu and Neufeld, 2003). While the above studies indicate that 
nuclear EGFR is a prognostic indicator for poor clinical outcome and nuclear expression of 
EGFR is associated with cancer development, all the studies have been correlative studies. 
Mechanistic investigations delineating oncogenic capacity of nuclear EGFR are still limited 
and need to be further addressed. Further, a systematic approach has, yet to be conducted to 
identify nuclear EGFR target genes. Knowledge of the target genes will advance our 
understanding of the nature and effect of nuclear EGFR on cell physiology, provide novel 
insights into the role of nuclear EGFR in human cancers, and help clarify some of the 
molecular mechanisms underlying the observed association between nuclear EGFR and 
poor clinical outcome.  
5. Role of EGFRvIII in the nucleus 
A substantial body of evidence suggests that the EGFRvIII contributes a strong oncogenic 
signal in GBM while simultaneously protecting them from conventional therapy (Hwang, 
2008; Gan et al., 2009). Two recent reports briefly described the nuclear localization of 
EGFRvIII in glial cells as well as glioblastoma (de, I et al., 2008; Lo et al., 2010). In 
glioblastoma, nuclear EGFRvIII was found to form a complex with STAT3 as was observed 
for EGFR. The EGFRvIII-STAT3 oncogenic complex was found to be essential for EGFRvIII 
induced transformation of astrocytes (de, I et al., 2008). Further, the second report of 
EGFRvIII nuclear localization showed that the EGFRvIII-STAT3 transcriptional complex 
could get recruited onto the promoter of Cox2 gene in glioma cells and increase 
transcription of Cox2 (Lo et al., 2010). Likewise, our finding that EGFRvIII binds STAT5b 
and positively regulates the transcription of Aurora A and Bcl-XL is the first demonstration 
of a role for EGFR/STAT5 pathway in the nucleus. Importantly, we show that nuclear 
EGFRvIII cooperates with STAT5b to regulate the Bcl-XL promoter and its expression in 
gliomas (Latha et. al., manuscript in preparation). This suggests that nuclear EGFR and 
EGFRvIII may be acting in concert with several members of the STAT family to generate a 
specific facet of its oncogenic signal in the nucleus and they also provide a potential role for 
combination therapy targeting EGFR/EGFRvIII and STAT5.The above studies suggest that 
the EGFRvIII-STAT family axis is important in gliomas. Although the above studies have 
shown nuclear translocation of EGFRvIII, the mechanism of translocation as well as the 
oncogenic role of EGFR in the nucleus remains unkown. Our recent investigation has shown 
that in gliomas, nuclear EGFRvIII as well as EGFR is membrane-derived and cycling of 
EGFRvIII and EGFR between the cytoplasm and nucleus is dependent on Importinβ and 
CRM1. Moreover, by manipulating EGFRvIII such that it is restricted to either the nucleus or 
the cytoplasm followed by functional studies, we show that nuclear EGFRvIII drives tumor 
formation. There is dramatic attenuation in the tumorigenic capacity of EGFRvIII upon 
blockade of its nuclear translocation in glioma cells (Gururaj et. al., manuscript in 
preparation). This suggests that while only a fraction of EGFRvIII or EGFR is in the nucleus, 
signaling here may be particularly important as it offers direct access to transcriptional 
regulators such as members of the STAT family. Taken together, these data provide an 
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important insight into a new signaling node that may make a unique and key contribution 
to the oncogenic signal from overactive and mutant EGFR. 
Nuclear expression EGFRvIII has also been described in prostate cancer (Edwards et al., 
2006) and invasive breast cancer. In hormone-refractory prostate cancer, nuclear expression 
of EGFRvIII was associated with decreased time to death from relapse and decreased overall 
survival (Edwards et al., 2006). EGFRvIII is associated with radioresistance as well as 
chemoresistance (Huang et al., 2009; Schmidt and Lichtner, 2002; Chakravarti et al., 2004), 
which may be related to nuclear localization, in light of the finding that EGFR’s association 
with nuclear targets is key to its ability to protect cells from DNA damaging agents, 
discussed above. In vitro studies using established glioma cell lines have shown that 
EGFRvIII confers resistance to cisplatin (Nagane et al., 1998; Nagane et al., 2000; Lammering 
et al., 2001; Lammering et al., 2003; Stea et al., 2003) and IR . Further, xenograft studies have 
shown that EGFR-specific inhibitors (small-molecule as well as α-EGFR antibodies) 
significantly enhance the efficacy of radiotherapy (Chakravarti et al., 2004; Harari and 
Huang, 2000). Also, EGFRvIII expression has been shown to enhance radioresistance by 
promoting the rapid repair of radiation-induced DNA double-strand breaks (Mukherjee et 
al., 2009). In line with this, a recent study showed that as with EGFR, EGFRvIII associates 
with DNA-PKcs after radiation and cisplatin treatment. They also showed that EGFRvIII not 
only conferred resistance to the two treatment modules but also significantly increased the 
activity of DNA-PKcs in cells (Liccardi et al., 2011). Recently, two independent studies 
showed that nuclear EGFR contributes to resistance to cisplatin treatment and cetuximab 
treatment (Hsu et al., 2009; Li et al., 2009). One of the studies also demonstrated that nuclear 
EGFR is required for DNA repair (Hsu et al., 2009). However, the role of nuclear EGFRvIII 
in either chemo- or radiation resistance in GBM is yet to be explored. 
6. Nuclear EGFR/EGFRvIII and therapeutics 
Since EGFR function is aberrantly regulated in a majority of the different epithelial cancers, 
attenuation of EGFR signaling is one of the key strategies for the management of human 
malignancies. Various therapeutic strategies have been developed to block EGFR signaling, 
with the most frequent strategies involving humanized monoclonal antibodies directed 
against EGFR, and small molecule tyrosine kinase inhibitors that target the enzymatic 
activity of the tyrosine kinase domain.  
Anti-receptor antibodies including cetuximab bind to the receptor extracellular domain and 
induce internalization and degradation, thus effectively blocking receptor activation of 
subsequent cellular signaling cascades. Cetuximab is currently used in combination with 
chemotherapy for treatment of metastatic colorectal cancers with EGFR expression and wt-
KRAS genotype as well as recurrent or metastatic head and neck squamous cell carcinoma 
(HNSCC). It is also indicated in treatment along with radiation for locally advanced 
HNSCC. As monotherapy, it is used in treatment of patients who have failed platinum 
based therapy of metastatic colorectal cancers. With respect to nuclear translocation of EGFR 
and cetuximab, there are conflicting data. In the context of radiation induced nuclear 
translocation, it was shown that cetuximab treatments results in accumulation of 
cytoplasmic EGFR and blockade of EGFR transport into the nucleus following radiation 
(Dittmann et al., 2005b). In contrast, a more recent study showed that cetuximab, like EGF, 
can induce nuclear localization of EGFR (Liao and Carpenter, 2009). However, it is to be 
noted that in this study, it was also shown that while EGF induced translocation required 
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kinase activity, cetuximab induced translocation was kinase independent (Liao and 
Carpenter, 2009). This could be due to a fundamental difference either in the trafficking or 
conformation of EGF- and cetuximab- bound EGFR and warrants further investigation. Of 
interest is another study demonstrating that cells which acquire resistance to cetuximab 
show increased localization of EGFR in the nuclear compartment (Li et al., 2009). Further, 
expression of EGFR tagged with NLS that show increased nuclear localization render cells 
resistant to cetuximab treatment both in vitro and in xenograft studies (Li et al., 2009). 
Collectively, these data suggest that the mechanisms of the effect of cetuximab on EGFR 
nuclear transport are likely to be complex and dependent on cellular context. Further 
research is necessary to clarify the role and effect of cetuximab in nuclear translocation of 
EGFR. Interestingly, a recent study also showed that a monoclonal antibody which 
recognizes EGFRvIII and activated EGFR, Mab 806, and which has been demonstrated to 
inhibit the growth of tumors expressing EGFRvIII or overexpressing EGFR, can sensitize 
radioresistant glioma cells expressing EGFRvIII (Johns et al., 2010). These findings provide a 
strong rationale for the study of nuclear EGFRvIII in resistance to therapy which has not 
been addressed thus far. 
Small molecule inhibitors such as erlotinib act against the cytoplasmic tyrosine kinase 
domain and inhibit the enzymatic activity of EGFR and so cytoplasmic signaling. Erlotinib is 
used as monotherapy for locally advanced or metastatic non-small cell lung cancer patients 
who have failed chemotherapy regimen and also for pancreatic cancer patients who have 
advanced local disease, metastasis or non-resectable tumors. However, there is insufficient 
evidence for using combinations of erlotinib with either chemotherapy or radiotherapy in 
patients and needs to be further investigated. Lapatinib, a dual EGFR and HER2 tyrosine 
kinase inhibitor, can sensitize cells to fluoropyrimidines possibly by inhibiting nuclear 
translocation of both EGFR and HER2 (Kim et al., 2009). Also, a recent study showed that 
nuclear EGFR is required for tumor resistance to DNA damage induced by the DNA 
alkylator, cisplatin (Hsu et al., 2009). Interestingly, a COX2 inhibitor, celecoxib has been 
shown to radiosensitize tumor cells by inhibiting radiation-induced nuclear EGFR 
translocation and DNA repair. Since this action of celecoxib did not correlate with COX2 
expression, it is suggested that it could be a COX2 independent mechanism (Dittmann et al., 
2008b). Another investigation demonstrated that the Src family kinase inhibitor, dasatinib 
could resensitize cells that were cetuximab resistant by inhibiting nuclear transport of EGFR 
(Li et al., 2009). While the above studies encourage the use of combination therapy to 
address treatment resistance by keeping EGFR out of the nucleus, we must proceed with 
caution since we are yet to understand the nuclear functions of EGFR in a comprehensive 
manner. Furthermore, such knowledge holds out the hope of leading to new targets that 
could be exploited in new combinations in the future. 
7. Conclusion 
Recent research has further strengthened the case for an important role of the EGFR family 
in a variety of cancers. It has also broadened our understanding of where these proteins may 
be active, by showing that in addition to propagating cytoplasmic signaling events, EGFR 
can also control other functions directly by translocating into the nuclear or mitochondrial 
compartment. Direct action within the nucleus could be a means by which the receptor 
achieves selectivity, specificity, and efficiency of gene activation not possible through shared 
transcription factors and second messenger/phosphorylation cascade systems. It may also 
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represent an ancient signaling connection between the limiting membrane and the genetic 
material and other vital cellular complexes that predate the evolution of intracellular, 
membrane bound organelles. Understanding the nuclear functions of EGFR as well as the 
mechanisms of its nuclear trafficking provides the hope of novel avenues for therapeutic 
interventions in various tumor types. Further, nuclear EGFR itself could be a new clinically 
relevant target with the potential to find application specifically in chemo- and radio-
resistant tumors. However, to evaluate the fitness of nuclear EGFR as a target, a selective 
inhibitor of EGFR transport needs to be identified. Thus, the current challenge in the field is 
to gain substantial knowledge about the functions as well as translocation of EGFR and 
define its role in cancer prognosis, targeting, and therapeutic sensitization. 
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